Fluzone Maker Sanofi Wants Language On Failed Confirmatory Study Added To Seqirus’ Fluad Label

 
• By Sue Sutter
  
Missed target
Sanofi wants a competitor's labeling to disclose a missed primary efficacy endpoint in a confirmatory trial. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Vaccines

More from Pink Sheet